87E Stock Overview

A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. More details

87E fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 60.1% per year

Revenue grew by 51.4% over the past year

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 19.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market

My Notes

Capture your thoughts, links and company narrative

Dianthus Therapeutics, Inc. Competitors

Formycon

XTRA:FYB

€927.0m

Biotest

XTRA:BIO3

€1.3b

Heidelberg Pharma

XTRA:HPHA

€101.6m

2invest

XTRA:2INV

€67.3m

Price History & Performance

Summary of share price highs, lows and changes for Dianthus Therapeutics
Historical stock prices
Current Share Price	US$22.80
52 Week High	US$29.60
52 Week Low	US$10.50
Beta	0
1 Month Change	1.79%
3 Month Change	-5.79%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	94.87%

Recent updates

Shareholder Returns

	87E	DE Biotechs	DE Market
7D	1.8%	1.2%	-0.3%
1Y	n/a	-14.3%	7.0%

Return vs Industry: Insufficient data to determine how 87E performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 87E performed against the German Market.

Price Volatility

Is 87E's price volatile compared to industry and market?
87E volatility
87E Average Weekly Movement	7.9%
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 87E's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 87E's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2019	53	Marino Garcia	dianthustx.com

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc. Fundamentals Summary

How do Dianthus Therapeutics's earnings and revenue compare to its market cap?
87E fundamental statistics
Market cap	€651.20m
Earnings (TTM)	-€64.46m
Revenue (TTM)	€5.16m

126.3x

P/S Ratio

-10.1x

P/E Ratio

Is 87E overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
87E income statement (TTM)
Revenue	US$5.37m
Cost of Revenue	US$0
Gross Profit	US$5.37m
Other Expenses	US$72.46m
Earnings	-US$67.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.27
Gross Margin	100.00%
Net Profit Margin	-1,250.32%
Debt/Equity Ratio	0%

How did 87E perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 11:30
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dianthus Therapeutics, Inc. is covered by 11 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joel Beatty	Baird
Pete Stavropoulos	Cantor Fitzgerald & Co.
Gavin Clark-Gartner	Evercore ISI